Main Article Content
Background: The association between liver fibrosis, assessed by transient elastography (TE), and methotrexate (MTX) treatment in patient with rheumatoid arthritis (RA) is not clear. Aims of this study were to assess the degree of liver stiffness with TE and to determine factors associated with liver fibrosis in patients receiving MTX.
Methods: We conducted a cross-sectional study in adult RA patients who were administrated MTX for more than 3 years. Transient elastography was performed. Significant liver fibrosis was defined as liver stiffness measurement (LSM) value ≥ 7 kPa. Associated factors were tested by logistic regression analysis.
Results: Among 264 rheumatoid arthritis included patients, 57 patients (21.6%) had significant liver fibrosis. The mean LSM value was 5.9±2.2 kPa. The mean cumulative dose of MTX was 3,640.7±1,452.0 mg. The mean duration of MTX usage was 6.4±2.8 years. Neither cumulative MTX doses nor MTX duration usage was correlated with liver stiffness measurement.
Conclusion: MTX induced liver fibrosis is uncommon in RA patients who had no underlying liver disease or predisposing factors for liver damage. Cumulative dose and duration of MTX requiring are probably unrelated to liver fibrosis.
Keywords: liver stiffness, liver fibrosis, transient elastgraphy, rheumatoid arthritis, methotrexate
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
2. Singh JA, Saag KG, Bridges Jr SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheum 2016;68:1-25.
3. Aithal GP. Hepatotoxicity related to antirheumatic drugs. Nat Rev Rheumatol 2011;7:139-50.
4. Nyfors A. Liver biopsies from psoriatics related to methotrexate therapy. Findings in post-methotrexate liver biopsies from 160 psoriatics. Acta Pathol Microbiol Scand [A] 1977;85:511-8.
5. Zachariae H, Kragballe K, Sogaard H. Methotrexate induced liver cirrhosis. Studies including serial liver biopsies during continued treatment. Br J Dermatol 1980;102:407-12.
6. Roenigk Jr HH, Auerbach R, Maibach HI, Weinstein GD. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1988;19:145-56.
7. Roenigk HH JR, Auerbach R, Maibach HI, Weinstein G, Lebwohl M. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998;38:478-85.
8. Kremer JM, Alarcón GS, Lightfoot RW Jr, Willkens RF, Furst DE, Williams HJ, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994; 37:316-28.
9. Hassan W. Methotrexate and liver toxicity: role of surveillance liver biopsy. Conflict between guidelines for rheumatologists and dermatologists. Ann Rheum Dis 1996;55:273-5.
10. Visser K, Katchamart W, Loza E, Martinez-Lopez J, Salliot C, Trudeau J, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a board panel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 2009;68:1086-93.
11. Aithal G, Haugk B, Das S, Card T, Burt A, Record C. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial biopsies justified? Aliment Pharmacol Ther 2004;19:391-9.
12. Visser K, van der Heijde DM. Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature. Clin Exp Rheumatol 2009;27:1017-25.
13. Laharie D, Seneschal J, Schaeverbeke T, Doutre MS, et al. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory disease: A case-control study. J Hepatol 2010;53:1035-40.
14. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001;344:495-500.
15. Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449-57.
16. Allan R, Thoirs K, Phillips M. Accuracy of ultrasound to identify chronic liver disease. World J Gastroenterol 2010;16:2510-20.
17. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008;48:835-47.
18. Marcellin P, Ziol M, Bedossa P, Douvin C, Poupon R, De Lédinghen V, et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. liver Int 2009;29:242-7.
19. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005;41:48-54.
20. Boursier J, Vergniol J, Guillet A, Hiriart JB, Lannes A, Le Bail B, et al. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by Fibroscan in non-alcoholic fatty liver disease. J Hepatol 2016;65:570-8.
21. Jung KS, Kim SU, Clinical applications of transient elastography. Clin Mol hepatol 2012;18:163-73.
22. Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta‐analysis. Hepatology 2017;66:1486-501.
23. Arena U, Stasi C, Mannoni A, Benucci M, Bongi SM, Cammelli D, et al. Liver stiffness correlates with methotrexate cumulative dose in patients with rheumatoid arthritis. Dig Liver Dis 2012;44:149-153.
24. Park SH, Choe JY, Kim SK. Assessment of liver fibrosis by transient elastography in rheumatoid arthritis patients treated with methotrexate. Joint Bone Spine 2010;77:588-592.
25. Kim TY, Kim JY, Sohn JH, Lee HS, Bang SY, Kim Y, et al. Assessment of substantial liver fibrosis by real-time shear wave elastography in methotrexate-treated patients with rheumatoid arthritis. J Ultrasound Med 2015;34:1621-1630.
26. Whittle SL, Hughes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatol 2004;43:267-71